Stock 605186 SHANGHAI GENERAL HEALTHY INFORMATION AND TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai General Healthy Information and Technology Co., Ltd.

Equities

605186

CNE100006BJ1

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
30.73 CNY -2.81% Intraday chart for Shanghai General Healthy Information and Technology Co., Ltd. -4.27% -26.38%
Apr. 29 Shanghai General Healthy Information and Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 29 Shanghai General Healthy Information and Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 65% by 2026.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.04 times its estimated earnings per share for the ongoing year.
  • The company appears highly valued given the size of its balance sheet.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI GENERAL HEALTHY INFORMATION AND TECHNOLOGY CO., LTD. Stock Shanghai General Healthy Information and Technology Co., Ltd.
-26.38% 577M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.56% 181B
C+
MEDTRONIC PLC Stock Medtronic plc
-0.11% 108B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-6.17% 66.12B
A
DEXCOM, INC. Stock DexCom, Inc.
+2.64% 50.65B
B-
CENCORA, INC. Stock Cencora, Inc.
+6.58% 43.11B
B-
HOYA CORPORATION Stock Hoya Corporation
+3.40% 41.3B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+21.98% 31.6B
B
TERUMO CORPORATION Stock Terumo Corporation
+16.81% 25.03B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-5.81% 24.16B
A-
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 605186 Stock
  4. Ratings Shanghai General Healthy Information and Technology Co., Ltd.